title: Treatment strategies for Parkinson's disease.
abstract: Parkinson's disease (PD) is caused by progressive degeneration of dopamine (DA) neurons in the substantia nigra pars compacta (SNpc), resulting in the deficiency of DA in the striatum. Thus, symptoms are developed, such as akinesia, rigidity and tremor. The aetiology of neuronal death in PD still remains unclear. Several possible mechanisms of the degeneration of dopaminergic neurons are still elusive. Various mechanisms of neuronal degeneration in PD have been proposed, including formation of free radicals, oxidative stress, mitochondrial dysfunction, excitotoxicity, calcium cytotoxicity, trophic factor deficiency, inflammatory processes, genetic factors, environmental factors, toxic action of nitric oxide, and apoptosis. All these factors interact with each other, inducing a vicious cycle of toxicity causing neuronal dysfunction, atrophy and finally cell death. Considerable evidence suggests that free radicals and oxidative stress may play key roles in the pathogenesis of PD. However, currently, drug therapy cannot completely cure the disease. DA replacement therapy with levodopa (L-Dopa), although still being a gold standard for symptomatic treatment of PD, only alleviates the clinical symptoms. Furthermore, patients usually experience severe side effects several years after the L-Dopa treatment. Until now, no therapy is available to stop or at least slow down the neurodegeneration in patients. Therefore, efforts are made not only to improve the effect of L-Dopa treatment for PD, but also to investigate new drugs with both antiparkinsonian and neuroprotective effects. Here, the advantages and limitations of current and future therapies for PD were dicussed. Current therapies include dopaminergic therapy, DA agonists, MAO-B inhibitor, COMT inhibitors, anticholinergic drugs, surgical procedures such as pallidotomy and more specifically deep brain stimulation of the globus pallidus pars interna (GPi) or subthalamic nucleus (STN), and stem cell transplantation.
authors.affiliation: Department of Integrated Traditional Chinese and Western Medicine, the General Hospital of Chinese People's Armed Police Forces , Beijing 100039, China. blsphd2005@126.com
authors.forename: Hong
authors.initials: H
authors.lastname: Yuan
authors.forename: Zhen-Wen
authors.initials: ZW
authors.lastname: Zhang
authors.forename: Li-Wu
authors.initials: LW
authors.lastname: Liang
authors.forename: Quan
authors.initials: Q
authors.lastname: Shen
authors.forename: Xiang-Dang
authors.initials: XD
authors.lastname: Wang
authors.forename: Su-Mei
authors.initials: SM
authors.lastname: Ren
authors.forename: Hong-Jie
authors.initials: HJ
authors.lastname: Ma
authors.forename: Shu-Jun
authors.initials: SJ
authors.lastname: Jiao
authors.forename: Ping
authors.initials: P
authors.lastname: Liu
mesh_terms: D000818:Animals; D006801:Humans; D010300:Parkinson Disease / Q000188:drug therapy / Q000503:physiopathology / Q000601:surgery / Q000628:therapy*